Clover Health Investments, Corp
Here’s whether Clover Health Investments, Corp (CLOV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+18.51% over 10 days); strong 1-year return of +61.4%; 3-month momentum positive (+140.1%); rising volume confirms the move (1.16x 30d avg). Concerns: RSI 70 — overbought, elevated pullback risk. Currently 8.7% off its 52-week high. Score: +6/7.
CLOV is in a confirmed uptrend, trading above both its 50-day ($3.05) and 200-day ($2.66) moving averages. With an RSI of 70.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +61.4% compares to +22.9% for SPY (beat the market by 38.6%).